Novel treatment options for ulcerative colitis

DSpace/Manakin Repository

Novel treatment options for ulcerative colitis

Citable link to this page

 

 
Title: Novel treatment options for ulcerative colitis
Author: Vaughn, Byron P; Moss, Alan C

Note: Order does not necessarily reflect citation order of authors.

Citation: Vaughn, Byron P, and Alan C Moss. 2013. “Novel Treatment Options for Ulcerative Colitis.” Clinical Investigation 3 (11) (November): 1057–1069. doi:10.4155/cli.13.97.
Access Status: Full text of the requested work is not available in DASH at this time (“dark deposit”). For more information on dark deposits, see our FAQ.
Full Text & Related Files:
Abstract: The approved treatment options for patients with ulcerative colitis (UC) are currently limited to mesalamine or immunosuppressants. Patients who do not respond to mesalamine-based therapy can be treated with immunomodulators or anti-TNF antibody therapy. Failure or adverse reactions to these medications leaves the patient with little choice other than colectomy. However, novel insights into the pathogenic drivers of UC have led to new developments in drugs that promise clinical efficacy via modulation of targeted pathways. Given the impending expansion of therapeutic options for patients with UC, clinicians and researchers should be familiar with these mechanisms of action. In addition, the typical ‘step-up’ treatment paradigm for UC will likely need to be reshaped to allow for a more personalized approach to treating UC.
Published Version: 10.4155/cli.13.97
Other Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3921900/
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:33942644
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters